Skip Navigation



JAC Advance Access published online on March 2, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl066
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/5/924    most recent
dkl066v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zarantonelli, M. L.
Right arrow Articles by Taha, M.-K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zarantonelli, M. L.
Right arrow Articles by Taha, M.-K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received November 4, 2005
Revised January 2, 2006
Accepted February 14, 2006

Original article

Immunogenicity of meningococcal PBP2 during natural infection and protective activity of anti-PBP2 antibodies against meningococcal bacteraemia in mice

Maria Leticia Zarantonelli 1 *, Aude Antignac 2, Marcelo Lancellotti 1, Annie Guiyoule 1, Jean-Michel Alonso 1, and Muhamed-Kheir Taha 1

1 Neisseria Unit, National Reference Center for Meningococci, Department of Molecular Medicine, Institut Pasteur, 25-28 rue du Dr Roux, 75724 Paris Cedex 15, France
2 Neisseria Unit, National Reference Center for Meningococci, Department of Molecular Medicine, Institut Pasteur, 25-28 rue du Dr Roux, 75724 Paris Cedex 15, France; Present address. Laboratory of Microbiology, The Rockefeller University, New York, New York 10021, USA

* To whom correspondence should be addressed.
Maria Leticia Zarantonelli, E-mail: lzaranto{at}pasteur.fr


  Abstract

Objective: To evaluate the immunogenicity of the meningococcal penicillin-binding protein 2 (PBP2) and its potential as a vaccine candidate.

Methods: The immunogenicity of meningococcal PBP2 was investigated using acute and convalescent sera from patients who recovered from meningococcal disease. Sera were tested against purified recombinant PBP2s corresponding to meningococcal isolates of different genetic lineages, of different serogroups and with various susceptibility levels to penicillin G. Mice were vaccinated with recombinant PBP2 and challenged with Neisseria meningitidis. A purified anti-PBP2 rabbit IgG was also used for passive protection experiments in mice.

Results: Convalescent patients' sera recognized PBP2s from different strains, showing that this protein is immunogenic in meningococcal disease. Vaccination with purified recombinant PBP2 and purified anti-PBP2 rabbit IgG antibody conferred protection against experimental meningococcaemia in mice.

Conclusion: These data argue for considering meningococcal PBP2 as a vaccine candidate.

Keywords: Neisseria meningitidis; vaccine; penicillin-binding proteins; animal model.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Infect. Immun.Home page
M.-L. Zarantonelli, M. Szatanik, D. Giorgini, E. Hong, M. Huerre, F. Guillou, J.-M. Alonso, and M.-K. Taha
Transgenic Mice Expressing Human Transferrin as a Model for Meningococcal Infection
Infect. Immun., December 1, 2007; 75(12): 5609 - 5614.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.